ReviewNature reviews. Drug discovery2012
Antibody-enabled small-molecule drug discovery.
Review in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 79 citations in OpenAlex.
- Structure-based screening of small-molecule interleukin-23 inhibitors inspired by monoclonal antibody interactions.Molecular diversity · 2026Article
- Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses.Frontiers in immunology · 2026Review
- Allosteric inhibition of trypanosomatid pyruvate kinases by a camelid single-domain antibody.eLife · 2025Article
- Which cryptic sites are feasible drug targets?Drug discovery today · 2024Review
- Peptide-Based Therapeutics in Cancer Therapy.Molecular biotechnology · 2024Review
- Arginine cluster introduction on framework region in anti-lysozyme antibody improved association rate constant by changing conformational diversity of CDR loops.Protein science : a publication of the Protein Society · 2023Article
- An equivariant generative framework for molecular graph-structure Co-design.Chemical science · 2023Article
- Targeting intracellular galectins for cancer treatment.Frontiers in immunology · 2023Review
- Identification and characterisation of anti-IL-13 inhibitory single domain antibodies provides new insights into receptor selectivity and attractive opportunities for drug discovery.Frontiers in immunology · 2023Article
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs.Frontiers in molecular biosciences · 2022Review
- A conformation-selective monoclonal antibody against a small molecule-stabilised signalling-deficient form of TNF.Nature communications · 2021Article
- Modulating Target Protein Biology Through the Re-mapping of Conformational Distributions Using Small Molecules.Frontiers in chemistry · 2021Article
- Spatiotemporal identification of druggable binding sites using deep learning.Communications biology · 2020Article
- New Chemical Modalities and Strategic Thinking in Early Drug Discovery.ACS medicinal chemistry letters · 2020Article
- Dynamic design: manipulation of millisecond timescale motions on the energy landscape of cyclophilin A.Chemical science · 2020Article
- Development and characterization of protein kinase B/AKT isoform-specific nanobodies.PloS one · 2020Article
- Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer.Nature communications · 2019Article
- AbPredict 2: a server for accurate and unstrained structure prediction of antibody variable domains.Bioinformatics (Oxford, England) · 2019Article
- An automated microfluidic system for selection of aptamer probes against ovarian cancer tissues.Biomicrofluidics · 2019Article
- Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment.Molecular cancer therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although antibody-based therapeutics have become firmly established as medicines for serious diseases, the value of antibodies as tools in the early stages of small-molecule drug discovery is only beginning to be realized. In particular, antibodies may provide information to reduce risk in small-molecule drug discovery by enabling the validation of targets and by providing insights into the design of small-molecule screening assays. Moreover, antibodies can act as guides in the quest for small molecules that have the ability to modulate protein-protein interactions, which have traditionally only been considered to be tractable targets for biological drugs. The development of small molecules that have similar therapeutic effects to current biologics has the potential to benefit a broader range of patients at earlier stages of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.